|
Patient characteristics |
||
| Number of patients |
N = 16 |
|
|
|
||
| Age |
||
| Median |
59 |
|
| Range |
36–73 |
|
| Male:female |
14:2 |
|
| ECOG performance status |
||
| 0 |
6 |
37% |
| 1 |
8 |
50% |
| 2 |
2 |
13% |
| Disease status |
||
| Primary metastatic |
12 |
75% |
| Locally-advanced |
4 |
25% |
| Prior chemotherapy |
||
| Uracil-tegafur |
4 |
25% |
| 5-FU bolus + folinic acid |
1 |
6% |
| 5-FU + cisplatin |
4 |
25% |
| Epirubicin + cisplatin + capecitabine |
5 |
31% |
| Epirubicin + doxorubicin + cisplatin |
2 |
13% |
Park et al. BMC Cancer 2005 5:87 doi:10.1186/1471-2407-5-87 |
||